PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study
Sign Up to like & getrecommendations! Published in 2020 at "Translational cancer research"
DOI: 10.21037/tcr-20-1333
Abstract: Gastric or esophagogastric junction cancer (GC/EGJC) is the third leading cause of cancer-related deaths worldwide, with most of the cases diagnosed at late stages (1,2). For patients (pts) with unresectable or recurrent advanced GC/EGJC, systemic… read more here.
Keywords: gastric esophagogastric; inhibitor combined; junction cancer; cancer ... See more keywords